What question did this study set out to answer?

To develop and compare microbial transglutaminase-mediated direct and chemo-enzymatic strategies for generating homogeneous antibody–drug conjugates with a precise drug-to-antibody ratio.

February 3, 2014Bioconjugate Chemistry

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

View Full Paper

Ask AI

Bookmark

Authors

PDPatrick DennlerPaul Scherrer Institute ACAristeidis ChiotellisNational Centre of Scientific Research "Demokritos"EFEliane FischerUniversity of Zurich

Discussion

Member takes

Implication

Preclinical study demonstrates uniform antibody-drug conjugate formation in breast cancer models, indicating a reliable strategy for targeted cancer therapies.

Key Points

To develop and compare microbial transglutaminase-mediated direct and chemo-enzymatic strategies for generating homogeneous antibody–drug conjugates with a precise drug-to-antibody ratio.
Evaluated direct one-step attachment of monomethyl auristatin E (MMAE) against a two-step chemo-enzymatic method utilizing microbial transglutaminase (MTGase) to site-specifically modify Gln295 on deglycosylated IgG heavy chains.
Tested bio-orthogonal cross-linking via thiol-maleimide chemistry and strain-promoted azide-alkyne cycloaddition (SPAAC) to attach MMAE derivatives.
Armed trastuzumab with MMAE using the MTGase-mediated SPAAC method and quantified in vitro cell-killing potency against BT-474 and SK-BR-3 breast cancer cell lines.
Direct enzymatic attachment required an 80-fold molar excess of toxin and yielded heterogeneous conjugates with a drug-to-antibody ratio (DAR) between 1.0 and 1.6.
The chemo-enzymatic approach required only a 2.5-fold molar excess of toxin, producing homogeneous conjugates with a DAR of 2.0 using SPAAC and 1.8 using thiol-maleimide chemistry.
Trastuzumab-MMAE generated via the chemo-enzymatic SPAAC route demonstrated potent in vitro cytotoxicity, killing BT-474 cells with an IC50 of 89.0 pM and SK-BR-3 cells with an IC50 of 21.7 pM.

Cite This Study

Dennler et al. (2014) studied this question.

synapsesocial.com/papers/69d687d9bcbb69330b88b60d https://doi.org/10.1021/bc400574z

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates uniform antibody-drug conjugate formation in breast cancer models, indicating a reliable strategy for targeted cancer therapies.

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

Discussion

Member takes

Implication

Key Points

Cite This Study

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider